Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study

Fig. 1

Tumor assessment of each patient in phase Ia (A) and Ib (B) dose escalation. (A) In phase Ia escalation of IBI110, the best response assessed by investigator was partial response (PR) in 1 patient and stable disease (SD) in 6 patients. After progressive disease (PD), patients may cross to combination treatment of IBI110 plus sintilimab while 8 patients had SD. (B) In phase Ib escalation of IBI110 plus sintilimab, 43 of 45 patients had undergone at least 1 post-baseline tumor assessment. The best response assessed by investigator was PR in 6 patients (4 non-small cell lung cancer, 1 small cell lung cancer and 1 endometrial cancer) and SD in 23 patients

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us